|
Corporate Presentation |
|
The selective PPAR-delta agonist seladelpar (MBX-8025) suppresses bile acid synthesis by reducing hepatocyte CYP7A1 through the FGF21 pathway |
|
Seladelpar Treatment of Patients With Primary Biliary Cholangitis (PBC) For 2 Years Improves the GLOBE PBC Score and Predicts Improved Transplant-Free Survival |
|
Comparative fibroreducing activities of selected nuclear receptor agonists in the carbon tetrachloride mouse model |
|
Seladelpar Treatment of Patients With Primary Biliary Cholangitis (PBC) For 2 Years Improves the GLOBE PBC Score and Predicts Improved Transplant-Free Survival |
